In a race against time, the World Health Organization (WHO) has triggered an emergency use authorization process for mpox vaccines as a growing outbreak spreads beyond the Democratic Republic of Congo (DRC). The move comes after a new viral strain, first detected in September 2023, was found outside the DRC, sparking concerns of a global health crisis.
The WHO Director-General announced the decision on August 7, 2024, citing “worrying trends” in the disease’s spread. The emergency use authorization process, known as EUL, will expedite the availability of unlicensed vaccines in public health emergency situations.
As the outbreak spirals out of control, the WHO is urging manufacturers to submit data to ensure the vaccines are safe, effective, and suitable for the target populations. The EUL will accelerate vaccine access, particularly for lower-income countries that have not yet issued their own national regulatory approval.
Mpox, a viral illness caused by the monkeypox virus, can be transmitted through physical contact, contaminated materials, or infected animals. With two vaccines already in use, the WHO’s Strategic Advisory Group of Experts on Immunization has recommended their use to combat the disease.
As the situation unfolds, the WHO’s swift action offers a glimmer of hope in the fight against mpox. With the EUL process underway, the global community holds its breath, waiting for the vaccines to reach those who need them most.
WHO/Ruth Abla ADJORLOLO
